Another example of a BiTE is elranatamab-bcmm/Elrexfio targeting CD3/B-cell maturation antigen (BCMA), a drug approved by the FDA for the treatment of multiple myeloma [88]. The gene discussed is TNFRSF17; the disease is plasma cell myeloma.